Search results for "GLP-1 Analogue"

showing 4 items of 4 documents

Comparison of DPP‐4 inhibition versus GLP‐1 analogue supplementation on survival and vascular complications in experimental sepsis (145.2)

2014

Background: Dipeptidyl peptidase [DPP]-4 inhibitors are a new class of drug for the treatment of hyperglycemia and recent studies revealed anti-inflammatory effects of these gliptins in experimenta...

DrugPathologymedicine.medical_specialtyendocrine system diseasesbusiness.industrymedia_common.quotation_subjectnutritional and metabolic diseasesPharmacologymedicine.diseaseBiochemistryDipeptidyl peptidaseSepsisGeneticsmedicineGLP-1 AnaloguebusinessMolecular BiologyDipeptidyl peptidase-4Biotechnologymedia_commonThe FASEB Journal
researchProduct

Similar effectiveness of dapagliflozin and GLP-1 receptor agonists concerning combined endpoints in routine clinical practice: A multicentre retrospe…

2019

Abstract Aims According to cardiovascular outcome trials, some sodium‐glucose contransporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are recommended for secondary cardiovascular prevention in type 2 diabetes (T2D). In this real‐world study, we compared the simultaneous reductions in HbA1c, body weight and systolic blood pressure after initiation of dapagliflozin or GLP‐1RA as second or a more advanced line of therapy. Materials and methods DARWIN‐T2D was a retrospective multi‐centre study conducted at diabetes specialist clinics in Italy that compared T2D patients who initiated dapagliflozin or GLP‐1RA (exenatide once weekly or liraglutide). Data were c…

Blood GlucoseMaleGlycated Hemoglobin AEndocrinology Diabetes and MetabolismBlood PressureType 2 diabetes030204 cardiovascular system & hematologySettore MED/13 - Endocrinologiachemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesClinical endpointMedicineDapagliflozinGLP-1 analogueMiddle AgedTreatment Outcomeglycaemic controlantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational studyCombinationOriginal ArticleDrug Therapy CombinationFemaleType 2medicine.drugAdultmedicine.medical_specialty030209 endocrinology & metabolismGlucagon-Like Peptide-1 Receptor03 medical and health sciencesDrug TherapyGLP-1 analogue; antidiabetic drug; dapagliflozin; glycaemic control; observational studyGLP‐1 analogueInternal medicineDiabetes mellitusInternal MedicineDiabetes MellitusHumansHypoglycemic AgentsBenzhydryl CompoundsAgedRetrospective StudiesGlycated Hemoglobinantidiabetic drugantidiabetic drug; dapagliflozin; GLP-1 analogue; glycaemic control; observational study; Adult; Aged; Benzhydryl Compounds; Blood Glucose; Blood Pressure; Body Weight; Diabetes Mellitus Type 2; Diabetic Angiopathies; Drug Therapy Combination; Exenatide; Female; Glucagon-Like Peptide-1 Receptor; Glucosides; Glycated Hemoglobin A; Humans; Hypoglycemic Agents; Liraglutide; Male; Middle Aged; Retrospective Studies; Treatment Outcomebusiness.industryLiraglutideBody WeightRetrospective cohort studyOriginal ArticlesdapagliflozinLiraglutidemedicine.diseaseBlood pressureDiabetes Mellitus Type 2chemistryPropensity score matchingExenatideobservational studybusinessAntidiabetic drug dapagliflozin GLP-1 analogue glycaemic control observational studyDiabetic Angiopathies
researchProduct

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

2009

Type 2 diabetes is a chronic, progressive disease with a multi-faceted pathophysiology. Beyond the known defects of insulin resistance and beta-cell insufficiency, derangement of incretin hormones normally produced from the gut wall in response to food intake play an important role. In recent years, the 'incretin-based' therapies (IBTs) have been developed to address hyperglycemia through either mimicking the action of the endogenous incretin glucagon-like polypeptide (GLP-1) (GLP-1 receptor agonists) or by inhibiting the activity of the enzyme that degrades GLP-1 (the dipeptyl peptidase-4 inhibitors).We reviewed available evidence on the glucose lowering and anti-atherogenic effects of IBT…

endocrine systemmedicine.medical_specialtyDipeptidyl Peptidase 410265 Clinic for Endocrinology and DiabetologyIncretin610 Medicine & healthType 2 diabetesCarbohydrate metabolismIncretinsInsulin resistancecardiovascular risk diabetes DPP-4 inhibitors GLP-1 analoguesGlucagon-Like Peptide 1Risk FactorsInternal medicineDiabetes mellitusmedicineAnimalsHumans2736 Pharmacology (medical)Pharmacology (medical)Dipeptidyl peptidase-4PharmacologyClinical Trials as TopicDipeptidyl-Peptidase IV Inhibitorsbusiness.industrydigestive oral and skin physiologyGeneral MedicineAtherosclerosismedicine.diseaseGlucose3004 PharmacologyEndocrinologyPostprandialDiabetes Mellitus Type 2aterosclerosibusinesshormones hormone substitutes and hormone antagonistsHormoneExpert Opinion on Investigational Drugs
researchProduct

Treatment by GLP-1 agonist modulates hedonic response to food and taste sensitivity in type 2 diabetes

2012

Context: Besides their potential action in the treatment of type 2 diabetes mellitus (T2DM), GLP-1 analogues have been shown to decrease satiety and food intake. However, little is known about their effects on food hedonic and taste perceptions. Objective: The objective of the study was to investigate the impact of GLP-1 analogue Liraglutide on the liking and wanting component of the food reward system as well as on taste sensitivity in T2DM patients. . Research design and methods: Thirty T2DM patients were studied before and after 3 months of daily Liraglutide treatment (1.2 mg). In each trial, blood samples were collected and body mass composition was analyzed by dual-energy X-ray absorpt…

GLP-1 analogue[SDV.AEN] Life Sciences [q-bio]/Food and Nutritionlikingnutrition[ SDV.AEN ] Life Sciences [q-bio]/Food and Nutritionsatietydigestive oral and skin physiology[SDV.BBM]Life Sciences [q-bio]/Biochemistry Molecular BiologygustationPHARMACOLOGY & PHARMACY[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct